-
After two pretreatment cycles, 196 patients with menorrhagia were randomized to tranexamic acid or placebo.
-
In this issue: Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
HPV infection is a major cause of morbidity in both genders. HPV vaccination (both bivalent and quadrivalent) has proved effective in girls and women, including those outside of the original age indications and those with prior sexual activity. Much less is known of vaccine efficacy in boys and men for the prevention of HPV-associated diseases.
-
While it is not in the top tier of contraceptive effectiveness, the diaphragm remains an option as a female-controlled method of birth control. What do you know about this form of family planning?
-
What is your practice when it comes to screening women for chlamydia? The Centers for Disease Control and Prevention (CDC) recommends annual chlamydia screening for all sexually active young women age 25 and younger.
-
Your next patient is a young woman who was in two months ago for a chlamydia infection. You provided her with a prescription and asked that she have her partner come in for evaluation, testing, and treatment.
-
While the human papillomavirus (HPV) vaccine has been approved for use in men, how many are open to receiving it? New research indicates men might be more willing to receive vaccination when they learn the vaccine can prevent cancer.
-
Findings from a new national report reflect an increase in the use of early medication abortion.
-
Many women might choose the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera) for its ease of use, but they might discontinue the method due to irregular bleeding.
-